Thrombosis in children with acute lymphoblastic leukemia: Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia

Thrombosis Research

Volumn 111, Issue 3, 2003, Pages 125-131

  Athale, Uma H ^a   Chan, Anthony K C ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Thromboembolism

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; STEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CARDIOVASCULAR RISK; CHILDHOOD CANCER; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME THERAPY; FATALITY; HEART ATRIUM THROMBOSIS; HEART RIGHT ATRIUM; HUMAN; IMMUNOPHENOTYPING; MORBIDITY; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEX RATIO; STATISTICAL SIGNIFICANCE; STEROID THERAPY; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; TREATMENT INDICATION;

EID: 0346849903     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.10.013     Document Type: Review

References (39)

1. SEER Cancer statistics review, 1973-1992. US Department of Health and Human Services, NIH publication No. 96-2789 p. 463.
2. Marina N. Long term survivors of childhood cancer: the medical consequences of cure. Pediatr. Clin. North Am. 44:1997;1021-1042.
3. Mitchell L.G., Sutor A.N., Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin. Thromb. Hemost. 21:1995;390-401.
4. Mongale P., Michelson A.D., Bovil E., Andrew M. Antithrombotic therapy in children. Chest. 119:2001;344S-370S.
5. van Ommen C.H., Heijboer H., Baller H.R., Hirasing R.A., Heijmano H.S.A., Peter M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J. Pediatr. 139:2001;676-681.
6. Priest J.R., Ramsay N.K.C., Steinherz P.G., Tubergen D.G., Cairo M.S., Sitarz A.L.et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J. Pediatr. 100:1982;984-989.
7. Pui C.H., Chesney C.M., Weed J., Jackson C.W. Altered von Willebrand molecule in children with thrombosis following asperaginase-prednisone- vicristine therapy for leukemia. J. Clin. Oncol. 3:1985;1266-1272.
8. Clavell L.A., Gelber R.D., Cohen H.J., Hitchcock-Bryan S., Cassady R.J., Tarbell N.J.et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. NEJM. 315:1986;657-663.
9. Miniero R., Saracco P., Einaudi S., Garofalo F., Lange M.M., Madon E. L-Asparaginase induced coagulopathy in children with acute lymphoblastic leukemia. Drugs Exp. Clin. Res. 13:1987;377-379.
10. Rodeghiero F., Castman G., Dini E. Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. Thromb. Res. 57:1990;31-38.
11. Gugliotta L., Mazzucconi M.G., Leone G., Mattioli-Belmonte M., Defazio D., Annino L.et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA study. Eur. J. Haematol. 49:1992;63-66.
12. Eckhof-Donovan S., Schwamborn D., Korholz D., Michelmann I., von Kries R., Nurnberger W.et al. Thrombosis in children with acute lymphoblastic leukemia treated with COALL protocol. Klin. Padiatr. 206:1994;327-330.
13. Castaman G., Rodeghiero F., Dini E. Thrombotic complications during L-asparaginase treatment for acute lymphoblastic leukemia. Haematologica. 75:1990;567-569.
14. Mitchell L., Hoogendoorn H., Giles A.R., Vegh P., Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparginase-induced antithrombin III deficiency. Blood. 83:1994;386-391.
15. Sutor A.H., Mall V., Thomas K.B. Bleeding and thrombosis in children with acute lymphoblastic leukemia, treated according to the ALL-BFM-90 protocol. Klin. Padiatr. 211:1999;201-204.
16. Shapiro A.D., Clarke S.L., Christian J.M., Odom L.F., Hathaway W.E. Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am. J. Pediatr. Hematol./Oncol. 15:1993;400-405.
17. Korte W., Feldges A., Baumgartner C., Ullmann S., Niederer V., Schmid L. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulibility in children with L-asparaginase therapy for ALL or NHL: a preliminary report. Klin. Padiatr. 206:1994;331-333.
18. Silverman L.B., Gelber R.D., Dalton V.K., Asselin B.L., Barr R.D., Clavell L.A.et al. Improved outcome of children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood. 97:2001;1211-1217.
19. Mauz-Korholz C., Junker R., Gobel U., Nowalk-Gottl U. Prothrombotic risk factors in children with acute lymphoblatic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb. Haemost. 83:2000;840-843.
20. Nowak-Gottl U., Wermes C., Junker R., Koch H.G., Schobess R., Fleischhack G.et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 93:1999;1595-1599.
21. Wermes C., Fleischhacck G., Junker R., Schobes R., Schwabe D., Sykora K.-W.et al. Cerebral venous sinus thrombosis in children with acute lymphoblastic leukemia carrying the MTHFR TT677 genotype and further prothrombotic risk factors. Klin. Padiatr. 211:1999;211-214.
22. Giordano P., Del Vecchio G.C., Santoro N.A.G., Coppola B., Altomare M., Schettini F.et al. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotype subgroup. Pediatr. Hematol. Oncol. 17:2000;667-672.
23. Kankirawatana S., Veerakul G., Sanpakit K., Tanphaichitr V.S., Akkabutr P., Suwantol L.et al. Thrombotic complications during induction chemotherapy of acute childhood lymphoblastic leukemia. J. Med. Assoc. Thai. 85:2002;S549-S557.
24. Mitchell L.G., Andrew M., Hanna K., Abshire T., Anderson R., Cherrick I.et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastc Leukemia Treated with Asparaginase (PARKAA) study. Cancer. 97:2003;508-516.
25. Male C., Chait P., Ginsberg J.S., Hanna K., Andrew M., Halton J.et al. Comparison of venography and ultrasound for the diagnosis of asymtomatic deep venous thrombosis in the upper body in children. Thromb. Haemost. 87:2002;593-598.
26. Nowak-Gottl U., Heinecke A., vonKries R., Nurnberger W., Munchow N., Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia. Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb. Res. 103:2001;165-172.
27. Ganick D.J., Robertson W.C. Jr., Viseskul C., Lubinsky M.S. Dural sinus thrombosis in leukemia. Am. J. Dis. Child. 132:1978;1040-1041.
28. Steinherz P.G., Miller L.P., Ghavimi F., Allen J.C., Miller D.R. Dural sinus thrombosis in children with acute lymphoblastic leukemia. JAMA. 246:1981;2837-2839.
29. Packer R.J., Rorke L.B., Lange B.J., Siegel K.R., Evans A.E. Cerebrovascular accidents in children with cancer. Pediatrics. 76:1985;194-201.
30. Feinberg W.M., Swenson M.R. Cerebrovascular complications of L-asparaginase therapy. Neurology. 38:1988;127-133.
31. Kieslich M., Porto L., Lanfermann H., Jacobi G., Schwabe D., Bohles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J. Pediatr. Hematol./Oncol. 25:2003;484-487.
32. Korones D.N., Buzzard C.J., Asselin B., Harris J.P. Right atrial thrombi in children with cancer and indwelling catheters. J. Pediatr. 128:1996;841-846.
33. Massicotte M.P., Dix D., Mongale P., Adams M., Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J. Pediatr. 133:1998;770-776.
34. David M., Andrew M. Venous thromboembolic complications in children. J. Pediatr. 123:1993;337-346.
35. Wermes C., Prondzinski M.V.D., Lichtinghagen M., Barthels K., Welte K., Sykora K.W. Clinical relevance of genetic risk factors for thrombosis in pediatric oncology patients with central venous catheters. Eur. J. Pediatr. 158(Suppl. 3):1999;S143-S146.
36. Athale U.H., Mah D., Davidson A., Nagel K., Odame I., Chan A.K.C. Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institution (DFCI) protocols: effect of age and risk stratification of ALL. Med. Ped. Oncol. 41:2003;310.
37. Ott N., Ramsay N.K.C., Priest J.R., Lipton M., Pui C.H., Steinherz P.et al. Sequel of thrombotic or haemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia. Am. J. Pediatr. Hematol./Oncol. 10:1988;191-195.
38. Margolin J.F., Steuber C.P., Poplack D.G. Acute lymphoblastic leukemia. Pizzo P.A., Poplack D.G. Principles and practice of pediatric oncology. 4th ed. 2002;488-544 Lippincot Williams & Wilkins, Philadelphia.
39. DeVeber G., Andrew M., Adams C., Bjornson B., Booth F., Buckley D.J.et al. Cerebral sinovenous in thrombosis children. NEJM. 345:2001;417-423.